Clinical calculator summary
EndoPredict EPclin Reported Risk-Class Interpreter, EPRG v4.2 (2025)
Clinical calculator summary
EndoPredict EPclin Reported Risk-Class Interpreter, EPRG v4.2 (2025)
Enter only the final quality-controlled, one-decimal EPclin score from the CE-marked IVD Eurobio EndoPredict Report Generator (EPRG) v4.2 (2025).
Evidence-based context for fast calculator use
- Purpose:
- Interprets a final externally generated one-decimal EPclin score from Eurobio EndoPredict Report Generator v4.2 (2025).
- Population:
- patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment
- Factors:
- Final Reported EPclin Score
EndoPredict EPclin Reported Risk-Class Interpreter, EPRG v4.2 (2025)
Enter the final report value to exactly one decimal place, from 1.0 through 6.0.
Clinical Context & Background
EPRG v4.2 final one-decimal lookup: EPclin 1.0-3.3 = Low; 3.4-6.0 = High. Values with precision beyond exact tenths are invalid and are never rounded.Reference Data
| Final EPclin score | Reported risk class | Version |
|---|---|---|
| 1.0-3.3 | Low | EPRG v4.2 (2025) |
| 3.4-6.0 | High | EPRG v4.2 (2025) |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use EndoPredict EPclin Reported Risk-Class Interpreter, EPRG v4.2 (2025) when interprets a final externally generated one-decimal EPclin score from Eurobio EndoPredict Report Generator v4.2 (2025).
- Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.
How To Interpret
- Interpret the displayed result using the calculator-specific formula and reference table, spanning 1.0-3.3 through 3.4-6.0.
- A boundary result should prompt input verification and clinical review rather than false precision.
What To Do Next
- Integrate the result with invasive versus in-situ status, stage, receptor biology, treatment timing, genomic testing, comorbidity, and patient goals.
- Document the inputs, result, timing, and clinical context so the assessment can be reproduced.
Limitations
- Do not interchange screening-risk, DCIS, invasive prognosis, genomic, and post-neoadjuvant tools.
- The result supports clinician judgment and does not independently determine treatment.
Validated Population
patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment
How to apply this result
For a representative case, verify Final Reported EPclin Score, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed cases passed through visible production controls at EPclin 1.0, 3.3, and the 3.4 High transition.
- The former unsupported three-band risk gauge was absent; only the source-defined Low and High classes were presented.
- No unexpected N/A, literal undefined value, stale control, unsupported gauge, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/endopredict-epclin-breast-cancer-2026-08-03.json.
: Local browser remediation
- The exact EPRG v4.2 Low/High result now explicitly suppresses the unsupported shared three-band Low/Intermediate/High gauge; the one-decimal lookup is unchanged.
- Ten source-backed cases passed through visible local browser controls across 11 submissions, including both exact bounds, the 3.3/3.4 transition, unsupported precision validation, and reset/repeat behavior.
- The existing calculator-specific audit passed 525/525. Production status remains open until this commit is deployed and the public route is revalidated.
Local case-level remediation evidence is retained in validation/browser-production/endopredict-epclin-breast-cancer.local-remediation.json.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 1/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-ui-and-console. high: Every classified result displays a generic Low Risk / Intermediate / High Risk gauge even though the EPRG v4.2 table has only Low (1.0-3.3) and High (3.4-6.0) classes; the added Intermediate label is unsupported. | medium: Production emitted minified React error #418 during the route load.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/endopredict-epclin-breast-cancer.json.
: Input workflow simplified and revalidated
- Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
- Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
- Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.
: Full validation test
- 525/525 independently expected identity, exact-tenth, class-parity, precision, legacy, malformed-input, applicability, wording, trace, UI, immutability, registry, inventory, report, history, and mirror assertions passed with zero class mismatch.
- This is source-to-code implementation verification, not independent clinical validation, individualized recurrence prediction, chemotherapy-benefit estimation, or treatment guidance.
: Correction
- Locked the permanent route to final one-decimal Eurobio EPRG v4.2 (2025) reported EPclin interpretation and separated legacy, high-precision, summary, and unidentified report versions.
- Corrected 3.3 to Low and 3.4 to High, rejected unsupported precision without rounding, added reported-class parity, and removed Number coercion and out-of-range fallthrough.
- Added exact population, specimen, therapy, pregnancy, QC, source, trace, snapshot, reset, and immutability gates and removed recurrence, late-risk, benefit, and treatment directives.
Included in the current validation report.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Related Tools
Frequently Asked Questions
When should EndoPredict EPclin Reported Risk-Class Interpreter, EPRG v4.2 (2025) be used?
Use it for patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment when all required inputs and the intended clinical setting are confirmed.
Can EndoPredict EPclin Reported Risk-Class Interpreter, EPRG v4.2 (2025) determine treatment by itself?
No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.
Evidence-based oncology decision support. Verify with clinical guidelines.